ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年06月23日 16時00分
Source:
Eisai
エーザイ、新株予約権証券の発行登録書の提出について
東京, 2020年06月23日 - (JCN Newswire) - 当社は、本日、「当社企業価値・株主共同の利益の確保に関する対応方針」(以下、本対応方針) に基づき、新株予約権証券の発行登録書を関東財務局に提出しました。本発行登録書の概要は下記の通りです。なお、本件は2019年6月21日に提出した発行登録書の期間(2019年7月1日から2020年6月30日)終了に対応するものです。
1.募集有価証券の種類:新株予約権証券
2.発行予定期間:発行登録の効力発生予定日から1年を経過する日まで(2020年7月1日から2021年6月30日)
3.募集方法:株主割当
4.発行予定額:8億円(上記は、新株予約権証券の発行価額の総額(無償)に新株予約権の行使に際して払い込むべき金額の合計額を合算した金額)
2020年6月19日に開催した取締役会において、社外取締役独立委員会より本対応方針を継続する旨の提案がなされ、審議の結果、提案通りに決議しました。本発行登録は機動的な株主割当による新株予約権発行を可能とするものです。
本対応方針の内容は、こちらをご参照ください。
(
https://www.eisai.co.jp/news/2020/pdf/news202028pdf.pdf
)
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202030.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Island States Ocean Summit Concludes Launch of the "OCEAN STATES INITIATIVE"
Jun 08, 2026 14:00 JST
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
Jun 04, 2026 23:49 JST
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Jun 04, 2026 23:17 JST
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Jun 04, 2026 22:46 JST
GR Premiers GRMN Corolla
Jun 04, 2026 22:05 JST
Island States Ocean Summit Opens in Tokyo
Jun 04, 2026 12:00 JST
Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Jun 04, 2026 00:26 JST
NEC Wins at the Newsweek AI Impact Awards 2026
Jun 04, 2026 00:09 JST
Mitsubishi Heavy Industries and Preferred Networks Form Business Alliance to Jointly Develop Japan-Made AI Technologies for Mission-Critical Applications
Jun 03, 2026 23:51 JST
JAL Engineering and Mitsubishi Heavy Industries Establish Joint Venture "Aero Breath" for Aircraft Aftermarket Business
Jun 03, 2026 23:27 JST
MHI Receives Waste Treatment Technology Verification Report from JESC for Its Biomass High-Efficiency Recovery and Recycling System AdBio
Jun 03, 2026 23:02 JST
DUNLOP and Fujitsu Reduce Tire Structural Analysis Time by Approximately 90% Using AI
Jun 03, 2026 22:31 JST
153 elevators and escalators delivered for the New Taipei Metro Sanying Line in Taiwan
Jun 03, 2026 11:00 JST
Fujitsu Launches AI-Powered Service to Analyze Non-Financial Disclosure and Enhance Corporate Value
May 29, 2026 22:11 JST
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
May 29, 2026 21:47 JST
Wheelchair Racer Catherine Debrunner Breaks Her Own World Record, Sets New Mark in the 200 Meters (T53) at the World Para Athletics Grand Prix (Switzerland)
May 27, 2026 22:45 JST
Fujitsu signs strategic partnership with Anthropic
May 27, 2026 22:03 JST
Fujitsu to accelerate AI transformation in Japan's enterprise sector through collaboration with OpenAI
May 27, 2026 21:18 JST
Hitachi Energy and Volvo Construction Equipment announce collaboration to accelerate zero-emission construction sites
May 27, 2026 20:19 JST
NEC and New York University Evaluate Economic Impact of Flood Protection Project Around the Island of Manhattan
May 27, 2026 12:03 JST
More Latest Release >>
Related Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
More Press release >>